vancomycin-resistant enterococcus

临床试验

计划入组 8 人 · 首次发布于 2008 年 1 月 11 日

已完成

NCT05200546

Carbapenemase-Producing Organism and Vancomycin-Resistant Enterococcus Management

计划入组 3,921 人 · 首次发布于 2022 年 1 月 20 日

Unknown

NCT00437580

Impact of Probiotic Regimen on Vancomycin Resistant Enterococcus Intestinal Carriage

计划入组 24 人 · 首次发布于 2007 年 2 月 21 日

药物

查看全部 148 →

Small Molecule

Approved

Quinupristin(Synercid)

相关疾病：Bacterial Infections, Methicillin Resistant Staphylococcus Aureus Infection (MRSA)，另有 1 项

C₅₃H₆₇N₉O₁₀S

Small Molecule

Approved

Dalfopristin(Synercid)

相关疾病：Bacterial Infections, Methicillin Resistant Staphylococcus Aureus Infection (MRSA)，另有 1 项

C₃₄H₅₀N₄O₉S

Small Molecule

Approved

Vancomycin(Firvanq, Vancocin)

生产企业：Viropharma inc, Lederle parenterals inc，另有 8 家

相关疾病：Clostridium Difficile Associated Diarrhea (CDAD), Enterocolitis caused by Staphylococcus aureus，另有 2 项

C₆₆H₇₅Cl₂N₉O₂₄ · Rx

机构

查看全部 11 →

Acurx Pharmaceuticals

United States

Cardiff Oncology

United States

Armata Pharmaceuticals

United States

资讯

查看全部 2923 →

3年前

Ampicillin Proves Effective Against VRE Urinary Tract Infections Despite Resistance Concerns

7个月前

Acurx Pharmaceuticals Secures New Patent for DNA Polymerase IIIC Inhibitors Targeting Antibiotic-Resistant Bacteria

11个月前

临床试验

The Influence of Probiotics on Vancomycin-Resistant Enterococcus

Carbapenemase-Producing Organism and Vancomycin-Resistant Enterococcus Management

Impact of Probiotic Regimen on Vancomycin Resistant Enterococcus Intestinal Carriage

药物

Quinupristin(Synercid)

Dalfopristin(Synercid)

Vancomycin(Firvanq, Vancocin)

机构

Acurx Pharmaceuticals

Cardiff Oncology

Armata Pharmaceuticals

资讯

Ampicillin Proves Effective Against VRE Urinary Tract Infections Despite Resistance Concerns

Acurx Pharmaceuticals Secures New Patent for DNA Polymerase IIIC Inhibitors Targeting Antibiotic-Resistant Bacteria

Acurx Pharmaceuticals Secures Australian Patent for Novel DNA Polymerase IIIC Inhibitor Antibiotics